Clinical Trials Browser

Phase 2 × Objective Response Rate × spartalizumab × Clear all

NCT05760196 2023-03-08

Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors

Phase 2 Unknown

Objective Response Rate